News

Novo Nordisk to invest $1.09 billion to boost Ozempic, Wegovy production in Brazil
Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...
Novo Nordisk's Head of Commercial Strategy Steps Down
Head of Novo's rare disease unit, Ludovic Helfgott, will immediately assume the responsibility for product and portfolio ...
Hosted on MSN24d
Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations
The largest absolute detractors were ICON plc, Novo Nordisk, and L'Oreal. Recent trial results for Novo Nordisk's next gen GLP-1, Cagrisema, came in below market expectations, sending the stock ...
Novo Nordisk (NVO) Will Invest $1.09B to Increase Production at Brazilian Factory
Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...
U.S. News & World Report19d
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...
Novo Holdings Nearly Doubles Earnings as Wegovy Swells Coffers
LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled ...
Novo Nordisk (0QIU) Gets a Buy from UBS
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Yahoo Finance25d
Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations
The largest absolute detractors were ICON plc, Novo Nordisk, and L'Oreal. Novo Nordisk (NVO) to be ‘Market Leader’ Despite ‘Horrifying’ Declines An elderly couple receiving insulin from a ...